ANNUAL REPORT FY2025 25 Relationship between the remuneration policy and Consolidated Entity performance The Board considers that at this time, evaluation of the Consolidated Entity's financial performance using generally accepted measures such as profitability, total shareholder return or benchmarking are not relevant as the Consolidated Entity is in the pre-clinical phase of drug development. 2025 Short-term employee benefits Postemployment benefits Share-based payments Total Salary & fees1 Bonus Other Superannuation Options and performance shares2 $ $ $ $ $ $ Non-executive Directors John Moore 203,915 - - - - 203,915 Rüdiger Weseloh 78,429 - - - - 78,429 Marcus Frampton 86,272 - - - - 86,272 Christopher Cox 86,272 - - - - 86,272 Ian Dixon 87,292 - - 4,837 - 92,129 Gisela Mautner3 68,974 - - 7,911 6,006 82,891 Executive employees James Bonnar (CEO)4 301,238 - 15,504 30,000 21,525 368,267 Total 912,392 - 15,504 42,748 27,531 998,175 1 Difference in Directors' salary & fess from financial year 2024 is due to the Directors voluntarily halving their director fees on 20 July 2023. Effective 1 April 2025, director fees were reinstated to the annual Non-Executive Director fees amounts stated below. 2 The value included in the share-based payment options column is calculated using sophisticated financial models. The expense is apportioned from the grant date to the date the options vest. As at the date of this report no KMP options have been exercised and this amount does not represent a cash benefit to the key management personnel. 3 Gisela Mautner share-based compensation derived from 1,800,000 share options granted during the period. 600,000 options vest on the first, second and third anniversary of the grant date subject to continuous employment. 4 James Bonnar share-based compensation derived from 3,200,000 share options granted during the period. The options vest over a three year period, and options will be fully vested and expensed on 11 June 2028.
RkJQdWJsaXNoZXIy MjE2NDg3